{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:14:23Z","timestamp":1779920063584,"version":"3.53.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"national natural science foundation of china for young scholars","award":["81702479"],"award-info":[{"award-number":["81702479"]}]},{"DOI":"10.13039\/501100021171","name":"guangdong basic and applied basic research foundation","doi-asserted-by":"crossref","award":["2020A151501281"],"award-info":[{"award-number":["2020A151501281"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"science and technology program of jiangmen, china","award":["2018630100110019805"],"award-info":[{"award-number":["2018630100110019805"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk of prolactinoma following the withdrawal of DAs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three medical databases, PubMed, EMBASE and Cochrane library, were retrieved up to February, 14, 2021 to identify studies related to recurrence of prolactinoma and withdrawal of DAs. Statistical analyses including meta-analysis, sensitivity analysis, meta-regression, funnel plot and Egger test were performed through software R.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 3225 studies were retrieved from the three data bases, and 13 studies consisted of 616 patients and 19 arms were finally included in this systematic analysis. There was no significant heterogeneity among the included studies, and fixed effect model was thus used. The pooled recurrence proportion of prolactinoma after withdrawal of DA was 2% with a 95% confidence interval (CI) of 1\u20133%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study showed a very low recurrent rate of prolactinomas after DAs withdrawal. Much more prospective studies with larger cases and longer follow-up period are encouraged to confirm our finding.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:bold>Registration number<\/jats:bold><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021245888\">CRD42021245888<\/jats:ext-link> (PROSPERO).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00889-1","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T12:02:59Z","timestamp":1636804979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Yunzhi","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-5546","authenticated-orcid":false,"given":"Xiaobing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"889_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/neuonc\/now130","volume":"19","author":"GU Mehta","year":"2017","unstructured":"Mehta GU, Lonser RR. Management of hormone-secreting pituitary adenomas. Neuro-Oncology. 2017;19:762\u201373. https:\/\/doi.org\/10.1093\/neuonc\/now130.","journal-title":"Neuro-Oncology"},{"issue":"2","key":"889_CR2","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"13","key":"889_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","volume":"362","author":"A Klibanski","year":"2010","unstructured":"Klibanski A. Prolactinomas. N Engl J Med. 2010;362(13):1219\u201326. https:\/\/doi.org\/10.1056\/NEJMcp0912025.","journal-title":"N Engl J Med"},{"issue":"2","key":"889_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388. https:\/\/doi.org\/10.1210\/jc.2010-1692.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"889_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P, J\u00f8rgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(1):43\u201351. https:\/\/doi.org\/10.1210\/jc.2009-1238.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"889_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","volume":"59","author":"MY Xia","year":"2018","unstructured":"Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50\u201361. https:\/\/doi.org\/10.1007\/s12020-017-1444-9.","journal-title":"Endocrine"},{"issue":"3","key":"889_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11102-016-0708-3","volume":"19","author":"SC Dogansen","year":"2016","unstructured":"Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S. Withdrawal of dopamine agonist therapy in prolactinomas: in which patients and when. Pituitary. 2016;19(3):303\u201310. https:\/\/doi.org\/10.1007\/s11102-016-0708-3.","journal-title":"Pituitary"},{"issue":"5","key":"889_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","volume":"18","author":"J Hu","year":"2015","unstructured":"Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary. 2015;18(5):745\u201351. https:\/\/doi.org\/10.1007\/s11102-014-0617-2.","journal-title":"Pituitary"},{"issue":"9308","key":"889_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(02)07882-0","volume":"359","author":"KF Schulz","year":"2002","unstructured":"Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet. 2002;359(9308):781\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(02)07882-0.","journal-title":"Lancet"},{"issue":"1","key":"889_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/ebmed-2017-110883","volume":"23","author":"D Nunan","year":"2018","unstructured":"Nunan D, Aronson J, Bankhead C. Catalogue of bias: attrition bias. BMJ evidence-based Med. 2018;23(1):21\u20132. https:\/\/doi.org\/10.1136\/ebmed-2017-110883.","journal-title":"BMJ evidence-based Med"},{"issue":"4","key":"889_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1210\/jcem-60-4-764","volume":"60","author":"P Moriondo","year":"1985","unstructured":"Moriondo P, Travaglini P, Nissim M, et al. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab. 1985;60(4):764\u201372. https:\/\/doi.org\/10.1210\/jcem-60-4-764.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"889_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40618-016-0483-z","volume":"39","author":"E Sala","year":"2016","unstructured":"Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, et al. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Investig. 2016;39(12):1377\u201382. https:\/\/doi.org\/10.1007\/s40618-016-0483-z.","journal-title":"J Endocrinol Investig"},{"issue":"9","key":"889_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/BF03348016","volume":"20","author":"M Muratori","year":"1997","unstructured":"Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Investig. 1997;20(9):537\u201346. https:\/\/doi.org\/10.1007\/BF03348016.","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"889_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00006254-200405000-00019","volume":"59","author":"A Colao","year":"2004","unstructured":"Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. Obstet Gynecol Surv. 2004;59(5):349\u201351. https:\/\/doi.org\/10.1097\/00006254-200405000-00019.","journal-title":"Obstet Gynecol Surv"},{"issue":"5","key":"889_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF03343573","volume":"22","author":"S Cannav\u00f2","year":"1999","unstructured":"Cannav\u00f2 S, Curt\u00f2 L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Investig. 1999;22(5):354\u20139. https:\/\/doi.org\/10.1007\/BF03343573.","journal-title":"J Endocrinol Investig"},{"issue":"8396","key":"889_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","volume":"324","author":"DG Johnston","year":"1984","unstructured":"Johnston DG, Taylor PK, Watson M, Hall K, Patrick D, Cook DB. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Lancet. 1984;324(8396):187\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(84)90480-X.","journal-title":"Lancet"},{"issue":"1","key":"889_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11102-007-0072-4","volume":"11","author":"ZB Wu","year":"2008","unstructured":"Wu ZB, Su ZP, Sen WJ, et al. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary. 2008;11(1):63\u201370. https:\/\/doi.org\/10.1007\/s11102-007-0072-4.","journal-title":"Pituitary"},{"issue":"1","key":"889_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11102-011-0303-6","volume":"15","author":"P Anagnostis","year":"2012","unstructured":"Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012;15(1):25\u20139. https:\/\/doi.org\/10.1007\/s11102-011-0303-6.","journal-title":"Pituitary"},{"issue":"8","key":"889_CR19","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","volume":"87","author":"VQ Passos","year":"2002","unstructured":"Passos VQ, Souza JJS, Musolino NRC, Bronstein MD. Long-term follow-up of prolactinomas: Normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002;87(8):3578\u201382. https:\/\/doi.org\/10.1210\/jcem.87.8.8722.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"889_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/cen.13240","volume":"86","author":"S Watanabe","year":"2017","unstructured":"Watanabe S, Akutsu H, Takano S, Yamamoto T, Ishikawa E, Suzuki H, et al. Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. Clin Endocrinol. 2017;86(2):207\u201313. https:\/\/doi.org\/10.1111\/cen.13240.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"889_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","volume":"67","author":"A Colao","year":"2007","unstructured":"Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol. 2007;67(3):426\u201333. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02905.x.","journal-title":"Clin Endocrinol"},{"issue":"7","key":"889_CR22","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94(7):2428\u201336. https:\/\/doi.org\/10.1210\/jc.2008-2103.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"889_CR23","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769\u201375. https:\/\/doi.org\/10.1210\/jc.2006-1668.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"889_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724\u201363. https:\/\/doi.org\/10.1210\/edrv.22.6.0451.","journal-title":"Endocr Rev"},{"issue":"1","key":"889_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/00006254-198601000-00016","volume":"41","author":"ME Molitch","year":"1986","unstructured":"Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. Obstet Gynecol Surv. 1986;41(1):48\u201350. https:\/\/doi.org\/10.1097\/00006254-198601000-00016.","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"889_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1530\/acta.0.0960024","volume":"96","author":"LG Sobrinho","year":"1981","unstructured":"Sobrinho LG, Nunes MC, Calhaz-Jorge C, Maur\u00edcio JC, Santos MA. Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours. Acta Endocrinol. 1981;96(1):24\u20139. https:\/\/doi.org\/10.1530\/acta.0.0960024.","journal-title":"Acta Endocrinol"},{"issue":"8","key":"889_CR27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00006254-199108000-00024","volume":"46","author":"JW Van\u2019t Verlaat","year":"1991","unstructured":"Van\u2019t Verlaat JW, Croughs RJM. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Obstet Gynecol Surv. 1991;46(8):566\u20138. https:\/\/doi.org\/10.1097\/00006254-199108000-00024.","journal-title":"Obstet Gynecol Surv"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00889-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00889-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00889-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:04:06Z","timestamp":1636848246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00889-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00889-1","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}